Which is the eligible patient to be treated with pioglitazone? The expert view
- PMID: 22234178
- DOI: 10.1007/BF03346725
Which is the eligible patient to be treated with pioglitazone? The expert view
Abstract
Pioglitazone has an important role in the treatment of patients with Type 2 diabetes. The drug can help patients to achieve sustained glycemic control and may delay the requirement for insulin. Pioglitazone may provide benefits beyond its effects on glycemia, with data suggesting it may confer anti-atherosclerotic and cardioprotective properties. Attention should be given to possible side effects relating to class effects of TZD, and selection of appropriate patients to be prescribed pioglitazone will enable optimum benefits to be derived from pioglitazone treatment.
Similar articles
-
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.Vasc Health Risk Manag. 2010 Apr 15;6:189-97. doi: 10.2147/vhrm.s5838. Vasc Health Risk Manag. 2010. PMID: 20407626 Free PMC article. Review.
-
Thiazolidinediones: the Forgotten Diabetes Medications.Curr Diab Rep. 2019 Nov 27;19(12):151. doi: 10.1007/s11892-019-1270-y. Curr Diab Rep. 2019. PMID: 31776781 Free PMC article. Review.
-
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.Expert Opin Pharmacother. 2007 Aug;8(12):1985-98. doi: 10.1517/14656566.8.12.1985. Expert Opin Pharmacother. 2007. PMID: 17696799 Review.
-
Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy.Endocr J. 2009;56(7):911-3. doi: 10.1507/endocrj.k09e-122. Epub 2009 Jun 9. Endocr J. 2009. PMID: 19506327
-
Pioglitazone: side effect and safety profile.Expert Opin Drug Saf. 2010 Mar;9(2):347-54. doi: 10.1517/14740331003623218. Expert Opin Drug Saf. 2010. PMID: 20175701 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical